CytoTronics Secures $13.5 Million in Seed Funding for Cell Biology Advancements “`

CytoTronics, a developer of semiconductor-based cell biology platforms, secured $13.5 million in Series Seed 2 funding. The company collaborated with Funden, a fundraising platform, to expand its investor network and achieve its funding goals.

Their product, Pixel, allows for high-resolution, multiplexed, real-time analysis of live cells, offering insights into how genetic or chemical changes affect cellular function. Pixel offers plate and reader options for various throughput needs, from research to high-throughput screening.

CytoTronics aims for Pixel to advance research in vascular, inflammatory, cardiovascular, neurological, rare, and oncological diseases. The technology’s ability to perform thousands of simultaneous, high-precision cellular experiments is expected to drive breakthroughs.

Duane Sword, CytoTronics’ Co-Founder and CBO, highlighted the challenges of attracting investors to novel hardware technologies. He noted the importance of demonstrating market demand to mitigate investor risk.

Funden assisted CytoTronics in refining their investor pitch, creating a more accessible narrative for broader investor audiences. Jake Casas, Funden’s VC-in-Residence, emphasized the significance of a compelling narrative, especially for complex technologies, in quickly conveying value propositions to potential investors.

Funden’s assistance led to over 200 investor connections and an additional $3 million in funding.

The Series Seed 2 round was led by LYFE Capital and Anzu Partners. New investors included Legend Star, RIT Venture Fund, and Draper Associates, all connected through Funden.

About CytoTronics 

CytoTronics uses high-throughput, semiconductor-based platforms to revolutionize cell biology research. Their Pixel platform provides live cell data at single-cell resolution across diverse cell types. By integrating semiconductors with standard microplates, Pixel enables multi-modal data acquisition, scaling cell biology research, drug development, and pharmaceutical manufacturing. Founded in 2021 as a Harvard University spin-off, they are based in Boston, Massachusetts. Learn more at www.cytotronics.com.

About Funden 

Funden streamlines fundraising for founders. Providing strategic guidance and curated introductions, Funden leverages a network of over 1,100 VCs and investors to facilitate high-quality investor meetings.

Media Contact

Siddharth Sareen

Source :Funden

“`